AGGXinactive
ANGIOGENEX, INC.
Biopharma developer (SEC filing verified)·Pre-clinical·CEO: Robert Benezra
OncologyOphthalmology
AGGX evidence brief
What we can confirm
No verified snapshot fields are available yet.
What it means
The company data is ready for cross-source review; unsupported conclusions remain unknown.
What to watch
Watch the next source-backed data update.
BioSniper AIPage evidence connected
Prepared research question
What matters most for AGGX—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
Market Cap
—
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2023.
Run ANGIOGENEX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ANGIOGENEX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Financials
Governance
Frequently asked questions
Who is the CEO of ANGIOGENEX, INC.?
Robert Benezra is the chief executive officer of ANGIOGENEX, INC. (AGGX).
What therapeutic areas does ANGIOGENEX, INC. focus on?
ANGIOGENEX, INC. develops therapies across Oncology, Ophthalmology.
925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.